Contrast induced nephropathy primary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 35: Line 35:
====N-acetylcysteine====
====N-acetylcysteine====


N-acetylcyteine (NAC) is a mycolytic agent and an antioxidant used in the treatment of acetaminophen overdose. Although studies on the use of NAC have variable results, a trend towards benefit from using NAC in addition to isotonic crystalloids prevails. Seven out of 11 meta-analyses on the effectiveness of NAC in preventing CIN have shown significant benefit.<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 | pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html  }} </ref> However, no data is present showing the contribution of NAC on the reduction of mortality and need for renal replacement therapy. Even large trials have shown little to no benefit of adding NAC. Still, given the modest evidence, the low cost, and the relative safety of NAC, most centers use it as part of the CIN prophylaxis regimen. The 2012 KDIGO guidelines recommend the use of NAC along with isotonic crystalloids.<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 | pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html  }} </ref>
N-acetylcyteine (NAC) is a mycolytic agent and an antioxidant used in the treatment of acetaminophen overdose. Although studies on the use of NAC have variable results, a trend towards benefit from using NAC in addition to isotonic crystalloids prevails. Seven out of 11 meta-analyses on the effectiveness of NAC in preventing CIN have shown significant benefit.<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 | pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html  }} </ref> However, no data is present showing the contribution of NAC on the reduction of mortality and need for renal replacement therapy. Even large trials have shown little to no benefit of adding NAC. Still, given the modest evidence, the low cost, and the relative safety of NAC, most centers use it as part of the CIN prophylaxis regimen. '''The 2012 KDIGO guidelines recommend the use of NAC along with isotonic crystalloids.'''<ref name="doi10.1038/kisup.2011.34">{{cite journal|author=Kidney Disease Improving Global Outcomes Work Group| title=2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury| journal=Kidey Int Supp |year= 2012 | volume= 2 | pages= 69-88 | doi=10.1038/kisup.2011.34 | pmc=|url=http://www.nature.com/kisup/journal/v2/n1/full/kisup201134a.html  }} </ref>


Two commonly used regimens are N-acetylcysteine (NAC) 600 mg orally twice daily, one day before the procedure and on the day of the procedure,<ref name="pmid12578487">{{cite journal |author=Kay J, Chow W, Chan T, Lo S, Kwok O, Yip A, Fan K, Lee C, Lam W|title=Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial |journal=JAMA |volume=289 |issue=5 |pages=553-8 |year=2003 |pmid=12578487}}</ref> or a  higher dose of 1200 mg orally twice daily for 2 days.<ref name="pmid16807414">{{cite journal |author=Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli A |title=N-acetylcysteine and contrast-induced nephropathy in primary angioplasty |journal=N Engl J Med |volume=354|issue=26 |pages=2773-82 |year=2006 |pmid=16807414}}</ref>.
'''Two commonly used regimens are N-acetylcysteine (NAC) 600 mg orally twice daily, one day before the procedure and on the day of the procedure,'''<ref name="pmid12578487">{{cite journal |author=Kay J, Chow W, Chan T, Lo S, Kwok O, Yip A, Fan K, Lee C, Lam W|title=Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial |journal=JAMA |volume=289 |issue=5 |pages=553-8 |year=2003 |pmid=12578487}}</ref> '''or a  higher dose of 1200 mg orally twice daily administered  in the similarly.'''<ref name="pmid16807414">{{cite journal |author=Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli A |title=N-acetylcysteine and contrast-induced nephropathy in primary angioplasty |journal=N Engl J Med |volume=354|issue=26 |pages=2773-82 |year=2006 |pmid=16807414}}</ref>.


====Theophylline====
====Theophylline====

Revision as of 16:10, 4 October 2013

Contrast Induced Nephropathy Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Pathophysiology

Differentiating Contrast induced nephropathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Contrast induced nephropathy primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Contrast induced nephropathy primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Contrast induced nephropathy primary prevention

CDC on Contrast induced nephropathy primary prevention

Contrast induced nephropathy primary prevention in the news

Blogs on Contrast induced nephropathy primary prevention

Directions to Hospitals Treating Contrast induced nephropathy

Risk calculators and risk factors for Contrast induced nephropathy primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Overview

Prevention

Strategies proposed to prevent the occurrence of CIN have been extensively studied but compelling evidence regarding the implementation of most of these approaches is still lacking. Prophylactic measures were recently defined in the 2012 KDIGO Guidelines and divided broadly into pharmacologic and non-pharmacologic approaches.

Non-Pharmacologic Approaches

Dose of contrast media

It has been shown that larger doses of contrast media are associated with higher risks of CIN. Still, no specific dose recommendations have been made due to lack of robust evidence. The 2012 KDIGO guidelines recommended using the smallest possible dose in every procedure requiring IV contrast especially in patients at high risk for developing CIN.[1] Nyman et al suggested an alternative approach, using the ratio of dose of iodine (in grams) to estimated glomerular filtration rate (eGFR). The team found the ratio to be predictive of the risk of CIN. A ratio I(g)/eGFR < 1 was shown to be relatively safe even in patients with many possible risk factors. The estimated risk decreased eightfold when the ratio dropped below 1.[2]

Route of Administration

Most studies illustrating the pathophysiology, treatment and prophylaxis of CIN focus on intra-arterial (IA) injection of contrast media considering it has been associated with the highest cases of CIN. A number of trials have also shown that intra-venous (IV) contrast has a significantly lower risk of CIN than IA contrast.[3][4] In fact, a review by Rao and Newhouse showed that in studies with proper controls, the risk of CIN after IV contrast administration did not differ between the study groups and the control groups.[5] This further emphasizes the importance of the route of contrast administration, and points to the fact that IV contrast has not been explicitly shown to be nephrotoxic.

Osmolarity of Contrast Agent

The osmolarity of the contrast medium has been clinically linked to differences in outcome. Initially, small scale studies showed no difference between high-osmolar and low-osmolar contrast media.[6] However, in 1995, a prospective randomized trial by Rudnick et al revealed that patients with renal insufficiency and diabetes mellitus had a significantly lower risk of CIN with low-osmolar media.[7] With the introduction of iso-osmolar media, several comparative studies most importantly the NEPHRIC trial by Aspelin et al showed that iso-osmolar media is highly superior in high risk patients with pre-existing renal disease and diabetes. The trial demonstrated that the incidence of CIN in the iso-osmolar contrast group was 3.1% compared with 26.2% in the low-osmolar contrast group.[8] Results of the NEPHRIC trial have sometimes been questioned to the lack of reproducibility in other trials. However, it is generally agreed that iso-osmolar contrast media pose the lowest risk of CIN among other contrast agents. The 2012 KDIGO Guidelines advocated the use of either iso-osmolar or low-osmolar iodinated contrast media, rather than high-osmolar media particularly in patients at increased risk of CIN.[1]

Preventative Strategies in CT scan - Click to Enlarge
Preventative Strategies in Angiography - Click to Enlarge

Pharmacologic Approaches

Volume Expansion

Volume expansion has been shown to significantly decrease the risk of CIN; however, no randomized control trials comparing fluids to placebo have been conducted. Results are extrapolated from comparison with historically untreated patients.[1] The mechanisms by which volume expansion decrease the risk of CIN may include dilution of the contrast media, increase in renal prostaglandins, counteraction of altered renal hemodynamics, and inhibition of the renin-angiotensin system. Many fluids have been investigated for expansion prior to contrast administration including normal saline (0.9%), hypotonic saline (0.45%), and isotonic sodium bicarbonate. Results of the studies comparing these fluids are variable and interpretation is not always easy given the significant limitations of these studies and the many confounding factors not accounted for.

Still, most studies suggest that fluid administration should be initiated 1-2 h before and maintained for 3–6 hours after contrast exposure.[1] Normal saline has been shown to be more effective than hypotonic saline in patients undergoing coronary angiography.[9] Bicarbonate has been suggested to be more efficacious than normal saline via additional benefits through free radical scavenging.[10] However, no robust evidence on the use of bicarbonate has been presented. A thorough meta-analysis of all randomized trials between 1950 and 2008 showed no clear benefit from bicarbonate expansion on the risk of mortality and dialysis.[11] In contrast, acetazolamide in combination with normal saline was found to be more beneficial than bicarbonate alone.[12] Nonetheless, the 2012 KDIGO guidelines did not recommend against the use of bicarbonate stating possible benefit but inconsistent data. They also recommended against the use of oral volume expansion.[1]

N-acetylcysteine

N-acetylcyteine (NAC) is a mycolytic agent and an antioxidant used in the treatment of acetaminophen overdose. Although studies on the use of NAC have variable results, a trend towards benefit from using NAC in addition to isotonic crystalloids prevails. Seven out of 11 meta-analyses on the effectiveness of NAC in preventing CIN have shown significant benefit.[1] However, no data is present showing the contribution of NAC on the reduction of mortality and need for renal replacement therapy. Even large trials have shown little to no benefit of adding NAC. Still, given the modest evidence, the low cost, and the relative safety of NAC, most centers use it as part of the CIN prophylaxis regimen. The 2012 KDIGO guidelines recommend the use of NAC along with isotonic crystalloids.[1]

Two commonly used regimens are N-acetylcysteine (NAC) 600 mg orally twice daily, one day before the procedure and on the day of the procedure,[13] or a higher dose of 1200 mg orally twice daily administered in the similarly.[14].

Theophylline

Interest in theophylline for CIN prophylaxis stems from the association of adenosine with the pathophysiology of CIN in certain studies.[15] Theophylline is a methylxanthine previously used for the treatment of asthma that also acts as an adenosine antagonist. Data about the use of theophylline is conflicting and several meta-analysis have shown little to not benefit from the use of theophylline prophylaxis.[16][17] However, more recent studies have shown some significant decrease in the risk of CIN when theophylline was compared to other prophylactic measures notably N-acetylcysteine and bicarbonate.[18][19] Still, the use of theophylline is not advocated given the limited data and the skewed risk to benefit ratio. Theophylline has many side effects including cardiac and CNS toxicity, and a very narrow therapeutic index entailing cautious use. The 2012 KDIGO guidelines recommend against the use of theophylline for CIN prophylaxis.

Statins

Recently, statins have been investigated as pre-treatment before contrast administration. Small scale studies have shown promise but no large scale randomized trials have been conducted.[1] One study by Yoshida et al showed that patients already with renal insufficiency on pravastatin treatment prior to contrast media exposure had a lower risk of CIN.[20] Very recently, results of the PRATO-ACS Study (Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome) reported that high-dose rosuvastatin (40 mg on-admission following by 20 mg/day) in patients presenting for ACS and scheduled for early PCI can prevent CIN and decrease the 30-day incidence of adverse cardiovascular and renal events.[21] Still, no recommendations about statin use prior to contrast administration have been made.

Fenoldopam

Fenoldopam is a selective dopamine A1 receptor agonist used as an anti-hypertensive with the added effect of increased renal medullary blood flow. Although small retrospective reviews showed benefit from using fenoldopam with isotonic saline, two randomized control trials showed no added benefit from using fenoldopam with saline compared to saline alone.[22][22] The 2012 KDIGO AKI guidelines recommend against using fenoldopam as a CIN prophylactic agent.[1]=

Other interventions

Other pharmacological agents, such as furosemide, mannitol, dopamine, and atrial natriuretic peptide have been tried, but have either not had beneficial effects, or had detrimental effects.[23][24]

Choice of contrast agent

The osmolality of the contrast agent has traditionally been believed to be of great importance in contrast-induced nephropathy. Ideally, the contrast agent should be iso-osmolar to blood. Modern iodinated contrast agents are non-ionic.

  • Hypo-osmolar, non-ionic contrast agents are beneficial if iso-osmolar, nonionic contrast media is not available due to costs.[25]

2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury (DO NOT EDIT)[26]

Nonpharmacological prevention strategies of CI-AKI

Level 1
"1. We recommend using either iso-osmolar or low-osmolar iodinated contrast media, rather than high-osmolar iodinated contrast media in patients at increased risk of CI-AKI. (Level of Evidence: 1B)"
Not Graded
"1. Use the lowest possible dose of contrast medium in patients at risk for CI-AKI. (Level of Evidence: Not Graded)"
Level 2
"1. We suggest not using prophylactic intermittent hemodialysis (IHD) or hemofiltration (HF) for contrast-media removal in patients at increased risk for CI-AKI. (Level of Evidence: 2C)"

Pharmacological prevention strategies of CI-AKI

Level 1
"1. We recommend i.v. volume expansion with either isotonic sodium chloride or sodium bicarbonate solutions, rather than no i.v. volume expansion, in patients at increased risk for CI-AKI. (Level of Evidence: 1A)"
"2. We recommend not using oral fluids alone in patients at increased risk of CI-AKI. (Level of Evidence: 1C)"
"3. We recommend not using fenoldopam to prevent CI-AKI. (Level of Evidence: 1B)"
Level 2
"1. We suggest using oral NAC, together with i.v. iso-tonic crystalloids, in patients at increased risk of CI-AKI. (Level of Evidence: 2D)"
"2. We suggest not using theophylline to prevent CI-AKI. (Level of Evidence: 2C)"

2011 ACCF/AHA/SCAI Guideline Recommendations: Pre-procedural Considerations (DO NOT EDIT)[27]

Contrast-Induced Acute Kidney Injury

Class I
"1. Patients should be assessed for risk of contrast-induced acute kidney injury before PCI.[28][29] (Level of Evidence: C)"
"2. Patients undergoing cardiac catheterization with contrast media should receive adequate preparatory hydration.[30][31][23][32] (Level of Evidence: B)"
"3. In patients with chronic kidney disease (CKD) (creatinine clearance <60 mL/min), the volume of contrast media should be minimized.[33][34][35] (Level of Evidence: B)"
Class III: Harm
"'1. Administration of N-acetyl-L-cysteine is not useful for the prevention of contrast-induced acute kidney injury.[36][37][38][39][40] (Level of Evidence: B)"

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Kidney Disease Improving Global Outcomes Work Group (2012). "2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury". Kidey Int Supp. 2: 69–88. doi:10.1038/kisup.2011.34.
  2. ↑ Nyman U, Björk J, Aspelin P, Marenzi G (2008). "Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention". Acta Radiol. 49 (6): 658–67. doi:10.1080/02841850802050762. PMID 18568558.
  3. ↑ Cramer BC, Parfrey PS, Hutchinson TA, Baran D, Melanson DM, Ethier RE; et al. (1985). "Renal function following infusion of radiologic contrast material. A prospective controlled study". Arch Intern Med. 145 (1): 87–9. PMID 3882071.
  4. ↑ Heller CA, Knapp J, Halliday J, O'Connell D, Heller RF (1991). "Failure to demonstrate contrast nephrotoxicity". Med J Aust. 155 (5): 329–32. PMID 1895978.
  5. ↑ Rao QA, Newhouse JH (2006). "Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis". Radiology. 239 (2): 392–7. doi:10.1148/radiol.2392050413. PMID 16543592.
  6. ↑ Tepel M, Aspelin P, Lameire N (2006). "Contrast-induced nephropathy: a clinical and evidence-based approach". Circulation. 113 (14): 1799–806. doi:10.1161/CIRCULATIONAHA.105.595090. PMID 16606801.
  7. ↑ Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF; et al. (1995). "Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study". Kidney Int. 47 (1): 254–61. PMID 7731155.
  8. ↑ 8.0 8.1 Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ; et al. (2003). "Nephrotoxic effects in high-risk patients undergoing angiography". N Engl J Med. 348 (6): 491–9. doi:10.1056/NEJMoa021833. PMID 12571256.
  9. ↑ Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U; et al. (2002). "Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty". Arch Intern Med. 162 (3): 329–36. PMID 11822926‎ Check |pmid= value (help). Review in: ACP J Club. 2002 Sep-Oct;137(2):44
  10. ↑ Caulfield JL, Singh SP, Wishnok JS, Deen WM, Tannenbaum SR (1996). "Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions". J Biol Chem. 271 (42): 25859–63. PMID 8824217‎ Check |pmid= value (help).
  11. ↑ Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M; et al. (2009). "Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy". Ann Intern Med. 151 (9): 631–8. doi:10.7326/0003-4819-151-9-200911030-00008. PMID 19884624. Review in: Ann Intern Med. 2010 May 18;152(10):JC5-10
  12. ↑ Assadi F (2006). "Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug". Pediatr Cardiol. 27 (2): 238–42. doi:10.1007/s00246-005-1132-z. PMID 16391986.
  13. ↑ Kay J, Chow W, Chan T, Lo S, Kwok O, Yip A, Fan K, Lee C, Lam W (2003). "Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial". JAMA. 289 (5): 553–8. PMID 12578487.
  14. ↑ Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli A (2006). "N-acetylcysteine and contrast-induced nephropathy in primary angioplasty". N Engl J Med. 354 (26): 2773–82. PMID 16807414.
  15. ↑ Arakawa K, Suzuki H, Naitoh M, Matsumoto A, Hayashi K, Matsuda H; et al. (1996). "Role of adenosine in the renal responses to contrast medium". Kidney Int. 49 (5): 1199–206. PMID 8731082.
  16. ↑ Bagshaw SM, Ghali WA (2005). "Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis". Arch Intern Med. 165 (10): 1087–93. doi:10.1001/archinte.165.10.1087. PMID 15911721.
  17. ↑ Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008). "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy". Ann Intern Med. 148 (4): 284–94. PMID 18283206‎ Check |pmid= value (help).
  18. ↑ Huber W, Eckel F, Hennig M, Rosenbrock H, Wacker A, Saur D; et al. (2006). "Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study". Radiology. 239 (3): 793–804. doi:10.1148/radiol.2393041456. PMID 16714461‎ Check |pmid= value (help).
  19. ↑ Baskurt M, Okcun B, Abaci O, Dogan GM, Kilickesmez K, Ozkan AA; et al. (2009). "N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy". Eur J Clin Invest. 39 (9): 793–9. doi:10.1111/j.1365-2362.2009.02173.x. PMID 19500141‎ Check |pmid= value (help).
  20. ↑ Yoshida S, Kamihata H, Nakamura S, Senoo T, Manabe K, Motohiro M; et al. (2009). "Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency". J Cardiol. 54 (2): 192–8. doi:10.1016/j.jjcc.2009.05.006. PMID 19782255.
  21. ↑ Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F (2013). "Early high-dose rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome. Results from Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome (PRATO-ACS Study)". J Am Coll Cardiol. doi:10.1016/j.jacc.2013.04.105. PMID 24076283.
  22. ↑ 22.0 22.1 Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y; et al. (2002). "Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy". Catheter Cardiovasc Interv. 57 (3): 279–83. doi:10.1002/ccd.10323. PMID 12410497‎ Check |pmid= value (help).
  23. ↑ 23.0 23.1 Solomon R, Werner C, Mann D, D'Elia J, Silva P (1994). "Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents". The New England Journal of Medicine. 331 (21): 1416–20. doi:10.1056/NEJM199411243312104. PMID 7969280. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  24. ↑ Abizaid AS, Clark CE, Mintz GS, Dosa S, Popma JJ, Pichard AD, Satler LF, Harvey M, Kent KM, Leon MB (1999). "Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency". Am J Cardiol. 83 (2): 260–3, A5. PMID 10073832.
  25. ↑ Schwab S, Hlatky M, Pieper K, Davidson C, Morris K, Skelton T, Bashore T (1989). "Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent". N Engl J Med. 320 (3): 149–53. PMID 2643042.
  26. ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID doi:10.1038/kisup.2011.34 Check |pmid= value (help).
  27. ↑ Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B; et al. (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions". Circulation. 124 (23): e574–651. doi:10.1161/CIR.0b013e31823ba622. PMID 22064601.
  28. ↑ Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G (2004). "A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation". Journal of the American College of Cardiology. 44 (7): 1393–9. doi:10.1016/j.jacc.2004.06.068. PMID 15464318. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  29. ↑ Moscucci M, Rogers EK, Montoye C, Smith DE, Share D, O'Donnell M, Maxwell-Eward A, Meengs WL, De Franco AC, Patel K, McNamara R, McGinnity JG, Jani SM, Khanal S, Eagle KA (2006). "Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions". Circulation. 113 (6): 814–22. doi:10.1161/CIRCULATIONAHA.105.541995. PMID 16461821. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  30. ↑ Bader BD, Berger ED, Heede MB, Silberbaur I, Duda S, Risler T, Erley CM (2004). "What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?". Clinical Nephrology. 62 (1): 1–7. PMID 15267006. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  31. ↑ Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H (2002). "Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty". Archives of Internal Medicine. 162 (3): 329–36. PMID 11822926. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  32. ↑ Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J (2003). "A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity". Nephron. Clinical Practice. 93 (1): C29–34. PMID 12411756. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  33. ↑ Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL (2009). "Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality". Annals of Internal Medicine. 150 (3): 170–7. PMID 19189906. Unknown parameter |month= ignored (help); |access-date= requires |url= (help)
  34. ↑ McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW (1997). "Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality". The American Journal of Medicine. 103 (5): 368–75. PMID 9375704. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  35. ↑ Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L (1995). "Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure". Journal of the American Society of Nephrology : JASN. 6 (5): 1451–8. PMID 8589322. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  36. ↑ Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL (2007). "A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity". BMC Medicine. 5: 32. doi:10.1186/1741-7015-5-32. PMC 2200657. PMID 18001477. Retrieved 2011-12-06.
  37. ↑ Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O (2007). "Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial". American Heart Journal. 154 (3): 539–44. doi:10.1016/j.ahj.2007.05.012. PMID 17719303. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  38. ↑ Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G (2010). "Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial". Journal of the American College of Cardiology. 55 (20): 2201–9. doi:10.1016/j.jacc.2009.08.091. PMID 20466200. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  39. ↑ Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, Sutander A, Williams T, Fox RS, Levin A (2004). "A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect". American Heart Journal. 148 (3): 422–9. doi:10.1016/j.ahj.2004.03.041. PMID 15389228. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)
  40. ↑ "Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)". Circulation. 124 (11): 1250–9. 2011. doi:10.1161/CIRCULATIONAHA.111.038943. PMID 21859972. Retrieved 2011-12-06. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Contrast_induced_nephropathy_primary_prevention&oldid=908688"